Myriad Genetics (MYGN) Short term Debt (2016 - 2025)

Myriad Genetics (MYGN) posted quarterly Short term Debt of $59.4 million for Q2 2025, down 42.94% quarter-over-quarter from $104.1 million in Q2 2021.

Myriad Genetics (MYGN) Short term Debt (2016 - 2025) Analysis & Trends

Myriad Genetics (MYGN) has reported Short term Debt for 7 consecutive years, with $59.4 million the latest figure, recorded in Q2 2025.

  • In Q2 2025, Short term Debt changed N/A year-over-year to $59.4 million; the TTM figure through Jun 2025 stood at $59.4 million (changed N/A YoY), while the FY2020 annual figure was $3.1 million, down 8.82% from the prior year.
  • Short term Debt declined to $59.4 million in Q2 2025 per MYGN's latest filing, from $104.1 million in the prior quarter.
  • Across five years, Short term Debt topped out at $104.1 million in Q2 2021 and bottomed at $59.4 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Thermo Fisher Scientific 213.88 Bn 209.81 Bn 8.34 Bn
2 Danaher 140.65 Bn 136.30 Bn 3.61 Bn
3 Idexx Laboratories 46.02 Bn 45.83 Bn 779.09 Mn
4 Agilent Technologies 39.85 Bn 38.05 Bn 990.00 Mn
5 Iqvia Holdings 39.20 Bn 37.12 Bn 1.44 Bn
6 Natera 38.80 Bn 37.70 Bn 696.04 Mn
7 Illumina 30.11 Bn 28.94 Bn 770.00 Mn
8 Mettler Toledo International 28.66 Bn 28.61 Bn 650.22 Mn
9 Quest Diagnostics 26.24 Bn 25.61 Bn 1.03 Bn
10 Myriad Genetics 297.97 Mn 173.57 Mn 137.60 Mn

Historic Data

Download Data
DateValue
Jun 30, 2025 59.40 Mn
Jun 30, 2021 104.10 Mn
Sep 30, 2020 3.30 Mn
Jun 30, 2020 3.10 Mn
Mar 31, 2020 3.10 Mn
Dec 31, 2019 3.40 Mn
Sep 30, 2019 3.30 Mn
Jun 30, 2019 3.40 Mn
Mar 31, 2019 3.70 Mn
Dec 31, 2018 5.30 Mn
Sep 30, 2018 5.30 Mn
Jun 30, 2018 5.30 Mn
Mar 31, 2018 7.40 Mn
Dec 31, 2017 70.00 Mn
Sep 30, 2017 54.00 Mn
Jun 30, 2017 127.30 Mn
Mar 31, 2017 128.20 Mn
Sep 30, 2016 199.20 Mn